J-Holdings Corp. (2721) · RiskFirst stated
Regulatory and Licensing Risks in the Regenerative Medicine Business
First written in FY2025-H1. . Latest entry: FY2025-H1.
1entries
1years
0from disclosures
How it moved
Same theme, other companies
Uncertainty over regulatory compliance, approvals and launch delays for pharmaceuticals and regenerative medicine productsA theme 37 companies write about · 40 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2022: 3 of 16 companies on the "Worse" side.
4 other companies' latest entry also says "First stated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.Full recordFilings, disclosures and news, newest first